---
title: "Cue BioPharma | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 2.954 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252731054.md"
published_at: "2025-08-12T20:01:51.000Z"
---

# Cue BioPharma | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 2.954 M

Revenue: As of FY2025 Q2, the actual value is USD 2.954 M, beating the estimate of USD 2 M.

EPS: As of FY2025 Q2, the actual value is USD -0.09, beating the estimate of USD -0.13.

### Segment Revenue

-   Collaboration revenue: $3.0 million for Q2 2025, compared to $2.7 million for Q2 2024. The increase was due to the timing of revenue earned from the collaboration and license agreement with Boehringer Ingelheim International GmbH (BI).

### Operational Metrics

-   Research and development expenses: $7.9 million for Q2 2025, compared to $9.5 million for Q2 2024. The decrease was primarily due to decreases in clinical trials costs and employee compensation.
-   General and administrative expenses: $3.7 million for Q2 2025, compared to $3.5 million for Q2 2024. The increase was primarily due to an increase in professional fees.
-   Loss from operations: - $8.6 million for Q2 2025, compared to - $10.4 million for Q2 2024.
-   Net loss: - $8.5 million for Q2 2025, compared to - $10.2 million for Q2 2024.

### Cash Flow

-   Cash and cash equivalents: $27.5 million as of June 30, 2025, compared to $22.5 million as of December 31, 2024.

### Unique Metrics

-   Raised approximately $20 million through a public offering.
-   Upfront payment of $12 million and ~$345 million in potential milestone payments from a strategic research collaboration and license agreement with Boehringer Ingelheim.

### Outlook / Guidance

-   The company plans to submit an IND for CUE-401 to address unmet needs in the treatment of autoimmune disease.
-   The company believes that CUE-101 has the potential to establish a new standard of care for HPV+ HNSCC patients.
-   The company anticipates potential receipt of future milestone-based payments.

### Related Stocks

- [CUE.US - Cue BioPharma](https://longbridge.com/en/quote/CUE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cue Biopharma 已確定 2026 年年度會議日期及提案提交截止日期 | Cue Biopharma 已將其 2026 年年度會議定於 2026 年 4 月 13 日，提案提交截止日期為 2026 年 2 月 28 日。該截止日期適用於股東提案、董事提名和代理徵集。CUE 股票的最新分析師評級為持有，目標價格為  | [Link](https://longbridge.com/en/news/276280551.md) |
| 沃爾瑪四季度財報超預期但盈利指引不及預期，CEO 稱 “美國低收入家庭只能勉強維持生計” | 沃爾瑪 Q4 營收超預期，新財年盈利指引（每股 2.75-2.85 美元）遠低於市場預期的 2.96 美元，顯示通脹壓力下消費者支出不確定性猶存，拖累股價下跌 1.38%。財報印證 K 型” 分化：高收入家庭驅動增長，低收入羣體 “錢包吃緊 | [Link](https://longbridge.com/en/news/276398633.md) |
| 谷歌突然發佈 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌發佈了最新的大模型 Gemini 3.1 Pro，其推理性能較去年發佈的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 評測中，Gemini 3.1 Pro 得分 77.1%，顯示出強大的推理能力。新模型支持多源數據綜合和複雜 | [Link](https://longbridge.com/en/news/276396515.md) |
| 學習英偉達刺激芯片銷售，AMD 為 “AI 雲” 借款做擔保 | AMD 為擴大市場份額祭出金融 “狠招”！為初創公司 Crusoe 的 3 億美元購芯貸款提供擔保，承諾在其無客户時 “兜底” 租用芯片。這一復刻英偉達 “租卡雲” 路徑的策略雖能短期推高銷量，但也令 AMD 在 AI 需求放緩時面臨更大的 | [Link](https://longbridge.com/en/news/276401504.md) |
| GRAIL｜8-K：2025 財年 Q4 營收 43.6 百萬美元超過預期 |  | [Link](https://longbridge.com/en/news/276379877.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
